Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor über 5 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | vor über 6 Jahren |
| Titel | Datum |
|---|---|
| MISC Commits RM40 Million to Develop Malaysia's Maritime Talent | vor 13 Tagen |
| Latest Tanker Adds Another Growth Opportunity For MISC | vor 22 Tagen |
| Stock Today: MISC Slips Amid Ammonia-Fuelled Tanker Milestone | vor 22 Tagen |
| MISC a buy after getting approval for ammonia-fuelled tanker - MBSB IB | vor 22 Tagen |
| MISC, SHI get BV's nod for 'world's first' ammonia-fueled LR2 tanker powered by PEMFC | vor 23 Tagen |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |